Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ariel Rojas Fabregat

General Practice San Juan, PR Medical Doctor

NPI 1689664377 CMS profile 410898

1056 Calle Ferrocarril, Ste 1, San Juan, PR 00925

Open in the dashboard

General payments

$917

15 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Ariel Rojas Fabregat of San Juan, PR is reported in the CMS Open Payments database as having received $917 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $77 1
2022 General $301 3
2021 General $214 3
2020 General $20 1
2019 General $304 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ariel Rojas Fabregat
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Ariel Rojas Fabregat were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Ariel Rojas Fabregat General Practice median Middle half National median
2019 $304 $107 $37–$285 $163
2020 $20 $75 $25–$213 $114
2021 $214 $93 $30–$272 $132
2022 $301 $103 $36–$279 $149
2023 $77 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Janssen Pharmaceuticals, Inc $328 5 payments
  2. GlaxoSmithKline, LLC. $244 2 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $162 2 payments
  4. Merck Sharp & Dohme Corporation $142 4 payments
  5. Sanofi-Aventis U.S. LLC $42 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $917 15 payments
Products named General payments · program years 2019–2023
  1. TRELEGY ELLIPTA $244 2 payments
  2. XARELTO $227 3 payments
  3. JANUMET $122 3 payments
  4. INVOKANA $71 2 payments
  5. JARDIANCE $67 1 payment
  6. INVEGA $55 1 payment
  7. JANUVIA $22 2 payments
  8. JANUMET XR $22 2 payments
  9. SOLIQUA 100/33 Diabetes $22 1 payment
  10. SOLIQUA 100/33 Endocrinology $20 1 payment
  11. Other $34 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 157 drugs

Part D claims

8,643

Median for General Practice: 1,105

Drug cost

$388,033

Median for General Practice: $48,734

Branded share of claims

20.8%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 87 $53,720
Januvia Sitagliptin Phosphate Brand 33 $32,144
Trijardy Xr Empaglifloz/Linaglip/Metformin Brand 40 $28,764
Jardiance Empagliflozin Brand 35 $27,725
Tradjenta Linagliptin Brand 15 $20,231
Xarelto Rivaroxaban Brand 26 $16,193
Janumet Sitagliptin Phos/Metformin Hcl Brand 24 $15,962
Breo Ellipta Fluticasone/Vilanterol Brand 37 $15,410
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 17 $13,936
Synthroid Levothyroxine Sodium Brand 149 $12,842

The 10 drugs with the highest cost, of 157 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record